Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication

被引:0
作者
Ting Xu
Xinqi Zhou
Jonathan W. Kanen
Lan Wang
Jialin Li
Zhiyi Chen
Ran Zhang
Guojuan Jiao
Feng Zhou
Weihua Zhao
Shuxia Yao
Benjamin Becker
机构
[1] University of Electronic Science and Technology of China,The Center of Psychosomatic Medicine, Sichuan Provincial Center for Mental Health, Sichuan Provincial People’s Hospital
[2] University of Electronic Science and Technology of China,MOE Key Laboratory for Neuroinformation, School of Life Science and Technology
[3] University of Cambridge,Department of Psychology
[4] University of Cambridge,Behavioural and Clinical Neuroscience Institute
[5] Max Planck School of Cognition,Faculty of Psychology
[6] Southwest University,Key Laboratory of Cognition and Personality
[7] Ministry of Education,undefined
来源
Molecular Psychiatry | 2023年 / 28卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adaptive human learning utilizes reward prediction errors (RPEs) that scale the differences between expected and actual outcomes to optimize future choices. Depression has been linked with biased RPE signaling and an exaggerated impact of negative outcomes on learning which may promote amotivation and anhedonia. The present proof-of-concept study combined computational modeling and multivariate decoding with neuroimaging to determine the influence of the selective competitive angiotensin II type 1 receptor antagonist losartan on learning from positive or negative outcomes and the underlying neural mechanisms in healthy humans. In a double-blind, between-subjects, placebo-controlled pharmaco-fMRI experiment, 61 healthy male participants (losartan, n = 30; placebo, n = 31) underwent a probabilistic selection reinforcement learning task incorporating a learning and transfer phase. Losartan improved choice accuracy for the hardest stimulus pair via increasing expected value sensitivity towards the rewarding stimulus relative to the placebo group during learning. Computational modeling revealed that losartan reduced the learning rate for negative outcomes and increased exploitatory choice behaviors while preserving learning for positive outcomes. These behavioral patterns were paralleled on the neural level by increased RPE signaling in orbitofrontal-striatal regions and enhanced positive outcome representations in the ventral striatum (VS) following losartan. In the transfer phase, losartan accelerated response times and enhanced VS functional connectivity with left dorsolateral prefrontal cortex when approaching maximum rewards. These findings elucidate the potential of losartan to reduce the impact of negative outcomes during learning and subsequently facilitate motivational approach towards maximum rewards in the transfer of learning. This may indicate a promising therapeutic mechanism to normalize distorted reward learning and fronto-striatal functioning in depression.
引用
收藏
页码:1692 / 1702
页数:10
相关论文
共 271 条
  • [1] Pessiglione M(2006)Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans Nature 442 1042-5
  • [2] Seymour B(2002)Getting formal with dopamine and reward Neuron 36 241-63
  • [3] Flandin G(2018)Neuroscience of apathy and anhedonia: a transdiagnostic approach Nat Rev Neurosci 19 470-84
  • [4] Dolan RJ(2015)Reinforcement learning in depression: a review of computational research Neurosci Biobehav Rev 55 247-67
  • [5] Frith CD(2020)Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression Brain 143 701-10
  • [6] Schultz W(2018)Impaired reward prediction error encoding and striatal-midbrain connectivity in depression Neuropsychopharmacology 43 1581-8
  • [7] Husain M(2021)Differential reinforcement learning responses to positive and negative information in unmedicated individuals with depression Eur Neuropsychopharmacology 53 89-100
  • [8] Roiser JP(2019)Neural correlates of weighted reward prediction error during reinforcement learning classify response to cognitive behavioral therapy in depression Sci Adv 5 eaav4962-5
  • [9] Chen C(1995)Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension Am J Cardiol 75 793-1003
  • [10] Takahashi T(2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995-404